Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life

Schumacher, Andrea; Riesenbeck, D.; Braunheim, Michael; Wewers, Dieter; Heinecke, Achim; Semik, M; Hoffknecht, Petra; Macha, H.-N.; Klinke, F.; Schmidt, E. W.; Willich, Normann; Berdel, Wolfgang E.; Thomas, Michael

doi:10.1016/j.lungcan.2003.10.004

Cited by 18 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is similar to that in other reports in the medical literature involving a wide variety of different malignancies. 7 We also found that fatigue worsened in frequency and intensity over the course of RT, as has also been reported in other studies. 13 Our study indicates that many of the symptoms varied depending on the specific cancer being treated.…”

Section: Discussionsupporting

confidence: 90%

Occurrence, Severity, and Longitudinal Course of Twelve Common Symptoms in 1129 Consecutive Patients During Radiotherapy for Cancer

Hickok

Morrow

Roscoe

et al. 2005

Journal of Pain and Symptom Management

154

120

View full text Add to dashboard Cite

Little is known about the frequency, severity, and course of symptoms experienced by patients receiving radiotherapy (RT). For this descriptive study, 1129 patients with a variety of cancer diagnoses completed a 12-item Symptom Inventory (SI) at the start of RT; 419 of these patients also completed the SI weekly for an additional 4 weeks (five data points). Eighty-four percent of the 1129 patients were already experiencing symptoms when treatment began. All symptoms significantly increased in frequency over a typical 5 week RT course (all Ps<0.001). Skin problems showed the largest increase. The most common symptoms (fatigue, drowsiness, and sleep problems) were also the most severe. Female patients and patients younger than the median age (59 years) reported significantly more symptoms than males and those 59 years or older. Symptom frequency and severity varied significantly by cancer diagnosis. Improved understanding about the time course and dose response of radiation-induced toxicity will permit more accurate presentation of side effect risk at the time patient consent is obtained.

show abstract

Section: Discussionsupporting

confidence: 90%

Occurrence, Severity, and Longitudinal Course of Twelve Common Symptoms in 1129 Consecutive Patients During Radiotherapy for Cancer

Hickok

Morrow

Roscoe

et al. 2005

Journal of Pain and Symptom Management

154

120

View full text Add to dashboard Cite

show abstract

“…The remaining 314 records dealt with the LC13; however, of these, 74 records were excluded because they did not present original data obtained by means of the module. Consequently, n = 240 articles were considered clinical studies according to our definition and were included in further analyses …”

Section: Resultsmentioning

confidence: 99%

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

Koller

Warncke

Hjermstad

et al. 2015

Cancer

View full text Add to dashboard Cite

13 (QLQ-LC13) covers 13 typical symptoms of lung cancer patients and was the first module developed in conjunction with the EORTC core qualityof-life (QL) questionnaire. This review investigates how the module has been used and reported in cancer clinical trials in the 20 years since its publication. Thirty-six databases were searched with a prespecified algorithm. This search plus an additional hand search generated 770 hits, 240 of which were clinical studies. Two raters extracted data using a coding scheme. Analyses focused on the randomized controlled trials (RCTs). Of the 240 clinical studies that were identified using the LC13, 109 (45%) were RCTs. More than half of the RCTs were phase 3 trials (n 5 58). Twenty RCTs considered QL as the primary endpoint, and 68 considered it as a secondary endpoint. QL results were addressed in the results section of the article (n 5 89) or in the abstract (n 5 92); and, in half of the articles, QL results were presented in the form of tables (n 5 53) or figures (n 5 43). Furthermore, QL results had an impact on the evaluation of the therapy that could be clearly demonstrated in the 47 RCTs that yielded QL differences between treatment and control groups. The EORTC QLQ-LC13 fulfilled its mission to be used as a standard instrument in lung cancer clinical trials. An update of the LC13 is underway to keep up with new therapeutic trends and to ensure optimized and relevant QL assessment in future trials.

show abstract

“…A majority of the included trials comparing various agent regimes shows no significant differences between treatment arms [13,15,21,29,31,41,44,47]. Another group of studies report cautious assumptions of HRQoL improvements [18,22,37].…”

Section: Resultsmentioning

confidence: 99%

Health-related quality of life questionnaires in lung cancer trials: a systematic literature review

2013

View full text Add to dashboard Cite

BackgroundLung cancer is one of the leading causes of cancer deaths. Treatment goals are the relief of symptoms and the increase of overall survival. With the rising number of treatment alternatives, the need for comparable assessments of health-related quality of life (HRQoL) parameters grows. The aim of this paper was to identify and describe measurement instruments applied in lung cancer patients under drug therapy.MethodsWe conducted a systematic literature review at the beginning of 2011 using the electronic database Pubmed.ResultsA total of 43 studies were included in the review. About 17 different measurement instruments were identified, including 5 generic, 5 cancer-specific, 4 lung cancer-specific and 3 symptom-specific questionnaires. In 29 studies at least 2 instruments were used. In most cases these were cancer and lung cancer-specific ones. The most frequently used instruments are the EORTC QLQ-C30 and its lung cancer modules LC13 or LC17. Only 5 studies combined (lung) cancer-specific questionnaires with generic instruments.ConclusionsThe EORTC-C30 and EORTC-LC13 are the most frequently used health-related quality of life measurement instruments in pharmacological lung cancer trials.

show abstract

Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life

Cited by 18 publications

References 26 publications

Occurrence, Severity, and Longitudinal Course of Twelve Common Symptoms in 1129 Consecutive Patients During Radiotherapy for Cancer

Occurrence, Severity, and Longitudinal Course of Twelve Common Symptoms in 1129 Consecutive Patients During Radiotherapy for Cancer

Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

Health-related quality of life questionnaires in lung cancer trials: a systematic literature review

Contact Info

Product

Resources

About